North America NGS Market to be Worth $13.7 Billion by 2030

North America NGS Market by Offering (Kits [Library Prep, QC, DNA Extraction], System) Type (Genome, Targeted) Application (Reproductive, Oncology, Infectious) Technology (SBS, Nanopore, SMRT Seq) — Forecast to 2030

Meticulous Research^®—a leading global market research company, published a research report titled, “North America NGS Market by Offering (Kits [Library Prep, QC, DNA Extraction], System) Type (Genome, Targeted) Application (Reproductive, Oncology, Infectious) Technology (SBS, Nanopore, SMRT Seq) - Forecast to 2030.”

According to this latest publication from Meticulous Research^®, the North America NGS Market is expected to reach $13.7 billion by 2030 at a CAGR of 16% from 2023 to 2030.The growth of the North America NGS market is attributed to several factors, including the rising prevalence of cancer, the increasing utilization of NGS in cancer research and treatment, the declining costs of sequencing procedures, advancements in sequencing technologies, the rising investments in pharmaceutical R&D, the increase in genome mapping programs, and the improvements in regulatory and reimbursement frameworks for NGS-based diagnostic tests. However, the high costs of NGS systems and consumables, the availability of alternative technologies, the low chances of identifying positive, actionable mutations for precision medicine, and ethical and legal issues related to NGS-based diagnosis restrain the growth of this market.

The increasing applications of NGS, the rising adoption of bioinformatics and genomic data management solutions, and government initiatives supporting large-scale genomic sequencing projects are expected to create growth opportunities for the players operating in the North America NGS market. However, the lack of skilled professionals and regulatory & standardization concerns in diagnostic testing are major challenges to market growth.

The increasing demand for NGS automation, the development of portable sequencing technologies, and increasing partnerships and collaborations among NGS instrument manufacturers to expand and improve product offerings are prominent trends in the North America next-generation sequencing market.

Key Players

The key players operating in the North America NGS market are Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), PerkinElmer, Inc. (U.S.), Qiagen N.V. (Netherlands), Agilent Technologies, Inc. (U.S.), Pacific Biosciences of California, Inc. (U.S.), Danaher Corporation (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Oxford Nanopore Technologies Plc. (U.K.), 10X Genomics, Inc. (U.S.), and Beijing Genomics Institute (BGI) (China).

North America NGS Market: Future Outlook:

The North America NGS market study presents historical market data in terms of values (2021 and 2022), estimated current data (2023), and forecasts for 2030. The North America NGS Market is segmented based on Offering (Consumables [Sample Preparation Consumables {DNA Extraction and Amplification, Library Preparation & Target Enrichment, Quality Control}, Other Consumables], NGS Platforms/Instruments, Software, Services), Sequencing Type (Targeted Genome Sequencing, Whole Genome Sequencing, Whole Exome Sequencing, Other Sequencing Types), Technology (Sequencing by Synthesis, Ion Semiconductor Sequencing, Single-molecule Real-time Sequencing (SMRT), Nanopore Sequencing, DNA Nanoball Sequencing), Applications (Clinical Applications [Reproductive Health, Oncology, Infectious Diseases, Other Clinical Applications], Research and Other Applications [Drug Discovery, Agriculture & Animal Research, Other Research Applications), End User (Hospitals and Diagnostic Laboratories, Pharmaceutical & Biotechnology Companies, Academic Institutes & Research Centers, Other End Users), and Country. The study also evaluates industry competitors and analyzes the market at the country level.

Among the offerings, in 2023, the consumables segment is expected to account for the largest share of the North America NGS market. The recurring use of consumables, rising demand for NGS-based diagnostic tests, and the increasing applications of NGS in oncology, reproductive health diagnosis, and drug discovery are increasing the demand for consumables.

Among the sequencing types, in 2023, the targeted genome sequencing segment is expected to account for the largest share of the North America NGS market. The large share of this segment is mainly attributed to its cost-effectiveness, its utilization in discovering somatic mutations in intricate samples like cancerous tumors mixed with germline DNA, and the substantial interest of researchers in utilizing targeted genome sequencing for exploring gene-drug associations.

Based on technology, the market is segmented into sequencing by synthesis, ion semiconductor sequencing, Single-molecule Real-time Sequencing (SMRT), nanopore sequencing, and DNA nanoball sequencing. Among these, the sequencing by synthesis segment is expected to account for the largest share of the North America NGS market in 2023. The large share of this segment is primarily attributed to the high accuracy of this technology in DNA sequencing, its capacity for high-yield error-free throughput, and its increasing integration within NGS products.

Among the applications, in 2023, the research and other applications segment is expected to account for the largest share of the North America NGS market. The growing prevalence of genetic disorders, the increasing adoption of sequencing-based tests in laboratories, the growing demand for personalized medicines, and the increasing NGS-based research are factors contributing to the significant market share of this segment.

Among the end users, in 2023, the pharmaceutical & biotechnology companies segment is expected to account for the largest share of the North America NGS market. The large market share of this segment is attributed to factors such as the increasing R&D spending by pharmaceutical & biotechnology companies and the rising incidence of chronic diseases, which drive the adoption of NGS among pharmaceutical & biotechnology companies.

Geographic Review

The North America NGS market is segmented into the U.S. and Canada. The U.S. is estimated to account for the larger share of the NGS market in 2023. The significant market share is primarily attributed to the increasing R&D investments within the pharmaceutical and biotechnology sector, the presence of key NGS market players in the country, supportive governmental programs for genomics research, the growing applications of NGS-based studies, the rising awareness about NGS-based tests, the rising incidence of cancer and genetic disorders, and the favorable reimbursement landscape in the U.S.

This research report provides a comprehensive analysis of the NGS market in North America (U.S. and Canada).

Download Sample Report Here @ https://www.meticulousresearch.com/download-sample-report/cp_id=5607

Key questions answered in the report:

Which are the high-growth market segments in terms of offering, sequencing type, technology, application, end user, and country?
What was the historical market for NGS across North America?
What are the market forecasts and estimates for the period 2023–2030?
What are the major drivers, restraints, challenges, opportunities, and trends in the North America NGS market?
Who are the major players in the North America NGS market?

Contact Us:
Meticulous Research®
Email- sales@meticulousresearch.com
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research